ASH News Daily 2017 - Issue 2 - C-8

ASH News Daily

Page C-8

Sunday, December 10, 2017

®

Exhibitor List
«« From Page C-7

Iron Disorders Institute ................................. 1860
ISH 2018 ........................................................... 1847
Isoplexis ........................................................... 2655
J-K-L
Janssen Biotech, Inc. ....................................... 1033
Janssen Pharmaceuticals, Inc. ....................... 1432
Jazz Pharmaceuticals, Inc. ............................. 2303
Jazz Pharmaceuticals, Inc. ............................. 2808
John Theurer Cancer Center - Hackensack
University Medical Hospital ..................... 2849
John Wiley & Sons, Inc. ................................. 2512
Juno Therapeutics ............................................ 523
Karius, Inc. ...................................................... 2755
Karyopharm Therapeutics, Inc. ................... 3215
Kite Pharma, Inc. ............................................ 2423
LeCancer.Fr/Publiclin ..................................... 239
Lymphoma Coalition ..................................... 1944
M-N-O
Machaon Diagnostics, Inc. ............................ 2950
Macopharma ................................................... 2151
Make-A-Wish America .................................. 1752
MaxCyte, Inc. .................................................... 413
Mayo Clinic Referring Physician Office...... 2141
Mayo Medical Laboratories .......................... 2123
McGraw-Hill Education .................................... 41
MDS Foundation, Inc..................................... 1640
Med Fusion ....................................................... 307
MediCom Oncology ...................................... 2244
Mediware ........................................................ 1553

Exhibit Hours
Today * 10:00 a.m. - 5:00 p.m.
Monday * 10:00 a.m. - 2:00 p.m.

Medscape Hematology/Oncology .............. 2548
Mendel Health ................................................ 2760
Merck & Co., Inc. ............................................ 1550
Merck & Co., Inc. ............................................ 1633
Midatech Pharma US, Inc. ............................ 1545
Miltenyi Biotec ................................................ 2532
Mission Bio, Inc. ............................................... 641
Moffitt Cancer Center .................................... 1941
MORE Health, Inc. ........................................... 507
MPE (Myeloma Patients Europe) ................ 1755
MPN Research Foundation........................... 1753
Multiple Myeloma Research Foundation ... 1641
NanoEnTek, Inc. ............................................. 3148
NanoString Technologies .............................. 2465
National Cancer Institute .............................. 1653
National Heart, Lung and Blood Institute.. 1655
National Marrow Donor Program/
Be The Match ............................................... 2040
Navigate BioPharma Services, Inc. ................ 341
NEJM Group ................................................... 2847
NeoGenomics Laboratories .......................... 1223
NIDDK/NIH .................................................. 1650
Northside Hospital Cancer Institute ........... 2946
Novamed North America ................................. 48
Novartis Oncology ......................................... 1601

Cancers evade
the immune system
in more than one way...

Novella Clinical .............................................. 1314
Novo Nordisk, Inc.......................................... 1523
Olympus America, Inc..................................... 740
Omeros Corporation ...................................... 2150
Oncology Group/ Div of UBM Medica ...... 2948
Oncology.TV ................................................... 1606
Ossium Health, Inc. ....................................... 2657
Otsuka America Pharmaceutical, Inc.
& Astex Pharmaceuticals, Inc. ................... 1533
Outcome Health ............................................... 613
P-Q-R
Pfizer (Rare Disease) ...................................... 2240
Pfizer Oncology .............................................. 2233
Pharmacyclics ................................................. 2515
PHARMANUTRA SpA (SIDERAL) .............. 233
Physicians' Education Resource, LLC ............. 30
Platelet Disorder Support Association ........ 1646
Portola Pharmaceuticals, Inc. ....................... 2248
PRA Health Sciences ........................................ 517
Precision Oncology ........................................ 2540
Predicine, Inc. ................................................. 3152
Premier Research ............................................ 1515
Prolong Pharmaceuticals .............................. 1351
Promega Corporation ...................................... 309
Prometic Life Sciences, Inc. ........................... 3209
PromoCell GmbH........................................... 2461
Prothena........................................................... 1610
PSI ....................................................................... 516
QIAGEN, Inc. .................................................. 2516
Quest Diagnostics .............................................. 46
QuintilesIMS ................................................... 3333
»» EXHIBITOR LIST Page C-9

Suppressor
cell

Macrophage
T cell

B cell

NK cell

© 2017 Celgene Corporation

10/17 US-CELG150347g(1)



Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 2

ASH News Daily 2017 - Issue 2 - A-1
ASH News Daily 2017 - Issue 2 - A-2
ASH News Daily 2017 - Issue 2 - A-3
ASH News Daily 2017 - Issue 2 - A-4
ASH News Daily 2017 - Issue 2 - A-5
ASH News Daily 2017 - Issue 2 - A-6
ASH News Daily 2017 - Issue 2 - A-7
ASH News Daily 2017 - Issue 2 - A-8
ASH News Daily 2017 - Issue 2 - A-9
ASH News Daily 2017 - Issue 2 - A-10
ASH News Daily 2017 - Issue 2 - A-11
ASH News Daily 2017 - Issue 2 - A-12
ASH News Daily 2017 - Issue 2 - A-13
ASH News Daily 2017 - Issue 2 - A-14
ASH News Daily 2017 - Issue 2 - A-15
ASH News Daily 2017 - Issue 2 - A-16
ASH News Daily 2017 - Issue 2 - A-17
ASH News Daily 2017 - Issue 2 - A-18
ASH News Daily 2017 - Issue 2 - A-19
ASH News Daily 2017 - Issue 2 - A-20
ASH News Daily 2017 - Issue 2 - A-21
ASH News Daily 2017 - Issue 2 - A-22
ASH News Daily 2017 - Issue 2 - A-23
ASH News Daily 2017 - Issue 2 - A-24
ASH News Daily 2017 - Issue 2 - A-25
ASH News Daily 2017 - Issue 2 - A-26
ASH News Daily 2017 - Issue 2 - A-27
ASH News Daily 2017 - Issue 2 - A-28
ASH News Daily 2017 - Issue 2 - B-1
ASH News Daily 2017 - Issue 2 - B-2
ASH News Daily 2017 - Issue 2 - B-3
ASH News Daily 2017 - Issue 2 - B-4
ASH News Daily 2017 - Issue 2 - B-5
ASH News Daily 2017 - Issue 2 - B-6
ASH News Daily 2017 - Issue 2 - B-7
ASH News Daily 2017 - Issue 2 - B-8
ASH News Daily 2017 - Issue 2 - B-9
ASH News Daily 2017 - Issue 2 - B-10
ASH News Daily 2017 - Issue 2 - B-11
ASH News Daily 2017 - Issue 2 - B-12
ASH News Daily 2017 - Issue 2 - B-13
ASH News Daily 2017 - Issue 2 - B-14
ASH News Daily 2017 - Issue 2 - B-15
ASH News Daily 2017 - Issue 2 - B-16
ASH News Daily 2017 - Issue 2 - B-17
ASH News Daily 2017 - Issue 2 - B-18
ASH News Daily 2017 - Issue 2 - B-19
ASH News Daily 2017 - Issue 2 - B-20
ASH News Daily 2017 - Issue 2 - B-21
ASH News Daily 2017 - Issue 2 - B-22
ASH News Daily 2017 - Issue 2 - B-23
ASH News Daily 2017 - Issue 2 - B-24
ASH News Daily 2017 - Issue 2 - B-25
ASH News Daily 2017 - Issue 2 - B-26
ASH News Daily 2017 - Issue 2 - B-27
ASH News Daily 2017 - Issue 2 - B-28
ASH News Daily 2017 - Issue 2 - B-29
ASH News Daily 2017 - Issue 2 - B-30
ASH News Daily 2017 - Issue 2 - B-31
ASH News Daily 2017 - Issue 2 - B-32
ASH News Daily 2017 - Issue 2 - B-33
ASH News Daily 2017 - Issue 2 - B-34
ASH News Daily 2017 - Issue 2 - B-35
ASH News Daily 2017 - Issue 2 - B-36
ASH News Daily 2017 - Issue 2 - B-37
ASH News Daily 2017 - Issue 2 - B-38
ASH News Daily 2017 - Issue 2 - B-39
ASH News Daily 2017 - Issue 2 - B-40
ASH News Daily 2017 - Issue 2 - B-41
ASH News Daily 2017 - Issue 2 - B-42
ASH News Daily 2017 - Issue 2 - B-43
ASH News Daily 2017 - Issue 2 - B-44
ASH News Daily 2017 - Issue 2 - B-45
ASH News Daily 2017 - Issue 2 - B-46
ASH News Daily 2017 - Issue 2 - B-47
ASH News Daily 2017 - Issue 2 - B-48
ASH News Daily 2017 - Issue 2 - B-49
ASH News Daily 2017 - Issue 2 - B-50
ASH News Daily 2017 - Issue 2 - B-51
ASH News Daily 2017 - Issue 2 - B-52
ASH News Daily 2017 - Issue 2 - B-53
ASH News Daily 2017 - Issue 2 - B-54
ASH News Daily 2017 - Issue 2 - B-55
ASH News Daily 2017 - Issue 2 - B-56
ASH News Daily 2017 - Issue 2 - C-1
ASH News Daily 2017 - Issue 2 - C-2
ASH News Daily 2017 - Issue 2 - C-3
ASH News Daily 2017 - Issue 2 - C-4
ASH News Daily 2017 - Issue 2 - C-5
ASH News Daily 2017 - Issue 2 - C-6
ASH News Daily 2017 - Issue 2 - C-7
ASH News Daily 2017 - Issue 2 - C-8
ASH News Daily 2017 - Issue 2 - C-9
ASH News Daily 2017 - Issue 2 - C-10
ASH News Daily 2017 - Issue 2 - C-11
ASH News Daily 2017 - Issue 2 - C-12
ASH News Daily 2017 - Issue 2 - C-13
ASH News Daily 2017 - Issue 2 - C-14
ASH News Daily 2017 - Issue 2 - C-15
ASH News Daily 2017 - Issue 2 - C-16
ASH News Daily 2017 - Issue 2 - C-17
ASH News Daily 2017 - Issue 2 - C-18
ASH News Daily 2017 - Issue 2 - C-19
ASH News Daily 2017 - Issue 2 - C-20
ASH News Daily 2017 - Issue 2 - C-21
ASH News Daily 2017 - Issue 2 - C-22
ASH News Daily 2017 - Issue 2 - C-23
ASH News Daily 2017 - Issue 2 - C-24
ASH News Daily 2017 - Issue 2 - C-25
ASH News Daily 2017 - Issue 2 - C-26
ASH News Daily 2017 - Issue 2 - C-27
ASH News Daily 2017 - Issue 2 - C-28
ASH News Daily 2017 - Issue 2 - C-29
ASH News Daily 2017 - Issue 2 - C-30
ASH News Daily 2017 - Issue 2 - C-31
ASH News Daily 2017 - Issue 2 - C-32
https://www.nxtbookmedia.com